Financial Performance - Revenue increased by 0.3% to HKD 1,393.3 million[2] - Profit attributable to equity holders (excluding government grants) rose by 6.8% to HKD 315.8 million[2] - Basic earnings per share remained at HKD 0.251[5] - Operating profit decreased by 3.4% to HKD 382.4 million[4] - EBITDA decreased by 4.4% to HKD 461.3 million, resulting in an EBITDA margin of 33.1%[47] - Financial income for 2024 was HKD 1,342,000, a recovery from a loss of HKD 4,608,000 in 2023[20] - The current tax expense for the group was HKD 72,138,000 in 2024, slightly down from HKD 72,238,000 in 2023, showing a decrease of around 0.1%[26] - The total tax expense for the year was HKD 73,324,000 in 2024, down from HKD 75,818,000 in 2023, indicating a decrease of about 3.3%[26] Dividends - Proposed final and special dividends are HKD 0.119 and HKD 0.054 per share, totaling HKD 0.173 per share, with an annual dividend of HKD 0.315 per share[2] - The annual dividend payout ratio is 125.5%, maintaining over 100% for nine consecutive years[2] - The interim dividend paid was HKD 165,810,000 in 2024, compared to HKD 163,545,000 in 2023, an increase of about 1.4%[31] - The proposed final dividend for 2024 is HKD 149,488,000, down from HKD 154,554,000 in 2023, reflecting a decrease of approximately 3.3%[32] - The board proposed a final and special dividend of HKD 0.119 and HKD 0.054 per share, respectively, with a total annual dividend of HKD 0.315 per share for the fiscal year ending March 31, 2024[70] Assets and Liabilities - Non-current assets decreased from HKD 544.0 million to HKD 524.7 million[6] - Total assets decreased from HKD 1,296.3 million to HKD 1,221.8 million[6] - Total equity decreased from HKD 612.3 million to HKD 496.8 million[7] - Cash and cash equivalents increased from HKD 439.2 million to HKD 567.4 million[6] - The right-of-use assets increased to HKD 260,748,000 in 2024 from HKD 231,573,000 in 2023, representing an increase of approximately 12.6%[22] - The total lease liabilities rose to HKD 268,726,000 in 2024, up from HKD 240,353,000 in 2023, indicating an increase of about 11.8%[23] - Cash outflows related to short-term leases amounted to HKD 8,160,000 in 2024, compared to HKD 6,383,000 in 2023, reflecting a rise of approximately 27.8%[24] - Interest expenses on lease liabilities decreased to HKD 11,224,000 in 2024 from HKD 12,523,000 in 2023, a decline of about 10.4%[24] Revenue Breakdown - Revenue from Hong Kong was HKD 1,081,377,000, up from HKD 1,040,119,000 in the previous year, while revenue from regions outside Hong Kong decreased to HKD 311,962,000 from HKD 349,142,000[13] - Revenue from Hong Kong operations increased by 4.0% to HKD 1,081.4 million, up from HKD 1,040.1 million in the previous fiscal year[49] - Revenue from Hong Kong operations accounted for 77.6% of the group's total revenue, compared to 74.9% in the previous fiscal year[50] - Revenue from operations outside Hong Kong decreased by 10.7% to HKD 311.9 million, down from HKD 349.2 million in the previous fiscal year[53] Employee and Operational Metrics - Employee benefits expenses totaled HKD 471,650,000, slightly increasing from HKD 470,570,000 in the previous year[16] - Employee benefits expenses increased slightly by 0.2% to HKD 471.7 million, consistent with revenue growth[45] - The group employed a total of 1,273 employees as of March 31, 2024, down from 1,317 employees a year earlier[63] Strategic Initiatives - The company’s strategic expansion includes the introduction of sleep therapy services, enhancing its portfolio in both medical and non-medical beauty services[39] - The company aims to enhance customer convenience and attract new customers through geographical expansion via flagship and community stores[39] - The company has strategically deployed resources in Hong Kong and mainland China to regain growth momentum post-pandemic[39] - The group strategically diversified into non-medical beauty services, launching "Goku Spa" in January 2024, with a focus on sleep therapy[51] - The group successfully opened "Goku Spa" locations in seven sites across Hong Kong, enhancing cross-selling opportunities[52] - The group aims to strengthen its presence in the high-end medical beauty market in mainland China, focusing on non-invasive beauty services[55] Compliance and Governance - The company has complied with the corporate governance code, except for the combined roles of the Chairman and CEO held by Dr. Ouyang Jiang[74] - The audit committee reviewed the financial statements for the year ending March 31, 2024, and discussed risk management and internal controls[77] - The company’s auditor, PwC, confirmed that the figures in the preliminary announcement align with the audited financial statements[78] - The annual report for the year ending March 31, 2024, will be sent to shareholders and available on the company’s website[80] Market Conditions - Hong Kong's GDP showed positive growth of 3.2% in 2023, with retail sales surging by 16.2%, although a slight decline of 1.3% was noted in Q1 2024 due to high base effects[39] - The group will closely monitor the business environment in Australia and Singapore due to inflationary pressures affecting operations[56] Capital Expenditures - Capital expenditures for 2024 were HKD 50,073,000, significantly higher than HKD 20,151,000 in 2023[16] - The group has committed capital expenditures of HKD 2.312 million for the acquisition of properties, plants, and equipment, an increase from HKD 1.474 million in the previous year[59]
完美医疗(01830) - 2024 - 年度业绩